TABLE 1.
Bacterial strains and plasmids used in this study
| Strain or plasmid | Relevant characteristicsa | Reference or source |
|---|---|---|
| Strains | ||
| V. vulnificus | ||
| C7184 | Clinical isolate | CDCb; J. Oliver |
| MO6-24/O | Opaque | J. G. Morris, Jr. (21) |
| CMM988 | crp mutant | This study |
| E. coli | ||
| CH1105 | MG1655 lacIqZΔM15 | H. E. Choy (5) |
| CH1019 | CH1105 Δcya854 | H. E. Choy (5) |
| CH1133 | CH1105 crp::P1 | H. E. Choy (5) |
| Plasmids | ||
| pCVD702 | pBR322 with vvhBA; Apr | J. G. Morris, Jr. (22) |
| pYB9801 | pUC18 with vvhBA; Apr | This study |
| pUCD615 | luxCDABE, oripSA, oripBR322; Apr, Kmr | C. I. Kado (14) |
| pYB9802 | pUCD615 with regulatory element of vvhBA | This study |
| pHA7 | pBR322 with crp of E. coli K-12 | S. Y. Yoo (1) |
| pYB9803 | pACYC184 with crp of E. coli K-12; Tcr | This study |
a
Apr, ampicillin resistant; Kmr, kanamycin resistant; Tcr, tetracycline resistant. When necessary, the appropriate antibiotics were added to the medium at the following concentrations; ampicillin, 100 μg/ml; kanamycin, 50 μg/ml; tetracycline, 10 μg/ml.
b
CDC, Centers for Disease Control and Prevention.